DelveInsight’s, “CAR-T Pipeline Insights 2023” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the CAR-T Pipeline Report
DelveInsight’s CAR-T pipeline report depicts a robust space with 120+ active players working to develop 460+ pipeline therapies for CAR-T treatment.
The leading companies working in the CAR-T Market include Ziopharm Oncology Inc. and Intrexon, Yake Biotechnology, Xyphos Biosciences, Xi’An Yufan Biotechnology, Wuhan Sian Medical Technology, Wuhan Bio-Raid Biotechnology, Wugen, WindMIL Therapeutics, Wellington Zhaotai Therapies, VorBio, VCANBIO Cell & Gene Engineering Corporation, Ltd, UWELL Biopharma, Transgene, TrakCel, ToolGen, Tmunity Therapeutics, Timmune Biotech, TILT Biotherapeutics, Tianjin Mycure Medical Technology, The Beijing Pregene Science and Technology Company, Tessa Therapeutics Ltd., TC BioPharm, Targazyme, Takeda / Noile-Immune Biotech, Synthekine, SymVivo, Sorrento Therapeutics, Sinobioway Cell Therapy Co., Ltd., Shenzhen BinDeBio, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Longyao Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Biomed-union Biotechnology, Servier, Sensei Biotherapeutics, Senlang Bio, Sangamo, Sana Biotechnology, REGENERON, PTX Therapeutics, Protheragen, Pregene (ShenZhen) Biotechnology Company, Precision BioSciences, Precigen, Poseida Therapeutics, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Pepromene bio, Oxford Biomedica, Orgenesis, Oncternal Therapeutics, Novartis Pharmaceuticals, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio, MolMed, Minerva Biotechnologies, Miltenyi Biotec, Medisix Therapeutics, Maxcyte, Luminary Therapeutics, Liminatus Pharma, Kuur Therapeutics, Kite Pharma, Kiromic BioPharma, Kecellitics Biotech Company Ltd, KAEDI, JW Therapeutics, Janssen Pharmaceuticals, Intellia Therapeutics, Innovent Biologics, Innovative Cellular Therapeutics, InnoBation, IN8Bio, Immunicum, Immuneel, Immune Therapeutics, iCell Gene Therapeutics, iCarTAB BioMed, Hunan Zhaotai Yongren Medical Innovation, Humorigin, HRAIN Biotechnology, Henan Hualong Biotechnology, Hemalogix, Helocyte, Helix BioPharma, Hebei Senlang Biotechnology Inc., Ltd., Guangzhou Bio-gene Technology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Grand Vista Biotechnology, Gracell Biotechnology, Glycotype, GlaxoSmithKline, Gilead Sciences, Genus oncology, GC Cell, Fundamenta Therapeutics, Fujifilm Holdings Corporation, Formula Pharmaceuticals, Fate Therapeutics, FastBack Bio, Exuma, Eutilex/Utilities, Eureka Therapeutics, Enlivex Therapeutics Ltd, Endocyte, and others.
Promising CAR-T Pipeline Therapies in the various stages of development include GC012F injection, Nivolumab, Autologous CD30, Fludarabine, Bendamustine, LCAR-B38M CAR-T Cell, WU-CART-007, CD70 CAR-T cells, SNC-109 CAR-T Cells, and others.
October 2023: Legend Biotech USA Inc. announced a study of Phase 1 clinical trials for LB1901. This is a Phase 1, first-in-human (FIH), open-label, multicenter, study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise specified [PTCL-NOS] and angioimmunoblastic [AITL]), or relapsed or refractory cutaneous T-cell lymphoma (CTCL) (Sézary syndrome [SS] and mycosis fungoides [MF]).
September 2023: Wugen Inc. announced a study of Phase 1 & 2 clinical trials for WU-CART-007. The main purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).
Request a sample and discover the recent advances in CAR-T Treatment Drugs @ CAR-T Pipeline Report
In the CAR-T pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
CAR-T Overview
CAR-T is a type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion.
Find out more about CAR-T Therapeutics Assessment @ CAR-T Preclinical and Discovery Stage Products
CAR-T Emerging Drugs Profile
JWCAR029: JW Therapeutics
CT 103A: Innovent Biologics
CEA CAR T: Sorrento Therapeutics
Descartes-11: Cartesian Therapeutics
CTL119: Novartis
TT11: Tessa Therapeutics
CD19-targeted CAR-T cells: Sinobioway Cell Therapy
MB-CART2019.1: Miltenyi Biomedicine
EPCAM-targeted CAR T-cells: Sinobioway Cell Therapy
CAR-T Pipeline Therapeutics Assessment
There are approx. 120+ key companies which are developing the CAR-T therapies. The CAR-T companies which have their CAR-T drug candidates in the most advanced stage, i.e. Preregistration include, JW Therapeutics.
Learn more about the emerging CAR-T Pipeline Therapies @ CAR-T Clinical Trials Assessment
Scope of the CAR-T Pipeline Report
Coverage- Global
CAR-T Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
CAR-T Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
CAR-T Companies- Ziopharm Oncology Inc. and Intrexon, Yake Biotechnology, Xyphos Biosciences, Xi’An Yufan Biotechnology, Wuhan Sian Medical Technology, Wuhan Bio-Raid Biotechnology, Wugen, WindMIL Therapeutics, Wellington Zhaotai Therapies, VorBio, VCANBIO Cell & Gene Engineering Corporation, Ltd, UWELL Biopharma, Transgene, TrakCel, ToolGen, Tmunity Therapeutics, Timmune Biotech, TILT Biotherapeutics, Tianjin Mycure Medical Technology, The Beijing Pregene Science and Technology Company, Tessa Therapeutics Ltd., TC BioPharm, Targazyme, Takeda / Noile-Immune Biotech, Synthekine, SymVivo, Sorrento Therapeutics, Sinobioway Cell Therapy Co., Ltd., Shenzhen BinDeBio, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Longyao Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Biomed-union Biotechnology, Servier, Sensei Biotherapeutics, Senlang Bio, Sangamo, Sana Biotechnology, REGENERON, PTX Therapeutics, Protheragen, Pregene (ShenZhen) Biotechnology Company, Precision BioSciences, Precigen, Poseida Therapeutics, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Pepromene bio, Oxford Biomedica, Orgenesis, Oncternal Therapeutics, Novartis Pharmaceuticals, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio, MolMed, Minerva Biotechnologies, Miltenyi Biotec, Medisix Therapeutics, Maxcyte, Luminary Therapeutics, Liminatus Pharma, Kuur Therapeutics, Kite Pharma, Kiromic BioPharma, Kecellitics Biotech Company Ltd, KAEDI, JW Therapeutics, Janssen Pharmaceuticals, Intellia Therapeutics, Innovent Biologics, Innovative Cellular Therapeutics, InnoBation, IN8Bio, Immunicum, Immuneel, Immune Therapeutics, iCell Gene Therapeutics, iCarTAB BioMed, Hunan Zhaotai Yongren Medical Innovation, Humorigin, HRAIN Biotechnology, Henan Hualong Biotechnology, Hemalogix, Helocyte, Helix BioPharma, Hebei Senlang Biotechnology Inc., Ltd., Guangzhou Bio-gene Technology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Grand Vista Biotechnology, Gracell Biotechnology, Glycotype, GlaxoSmithKline, Gilead Sciences, Genus oncology, GC Cell, Fundamenta Therapeutics, Fujifilm Holdings Corporation, Formula Pharmaceuticals, Fate Therapeutics, FastBack Bio, Exuma, Eutilex/Utilities, Eureka Therapeutics, Enlivex Therapeutics Ltd, Endocyte, and others.
CAR-T Pipeline Therapies- GC012F injection, Nivolumab, Autologous CD30, Fludarabine, Bendamustine, LCAR-B38M CAR-T Cell, WU-CART-007, CD70 CAR-T cells, SNC-109 CAR-T Cells, and others.
Dive deep into rich insights for new drugs for CAR-T Treatment, Visit @ CAR-T Market Drivers and Barriers, and Future Perspective
Table of Content
Introduction
Executive Summary
CAR-T: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Preregistration)
JWCAR029: JW therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Descartes-11: Cartesian Therapeutics
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
CSG-CD19: Carsgen therapeutics
Drug profiles in the detailed report…..
Inactive Products
CAR-T Key Companies
CAR-T Key Products
CAR-T- Unmet Needs
CAR-T- Market Drivers and Barriers
CAR-T- Future Perspectives and Conclusion
CAR-T Analyst Views
CAR-T Key Companies
Appendix
For further information on the CAR-T Pipeline therapeutics, reach out to CAR-T Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking
